PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price objective upped by research analysts at Cantor Fitzgerald from $130.00 to $137.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 109.93% […]

Upexi (NASDAQ:UPXI – Get Free Report) had its price objective increased by Cantor Fitzgerald from $1.30 to $2.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 93.24% from the stock’s current price. […]